<DOC>
	<DOCNO>NCT00963417</DOCNO>
	<brief_summary>RATIONALE : Gathering information time bone density laboratory test woman breast cancer treat triptorelin tamoxifen exemestane may help study breast cancer future . PURPOSE : This clinical trial study change bone mineral density woman breast cancer treat triptorelin tamoxifen exemestane protocol IBC SG-25-02 ( TEXT ) .</brief_summary>
	<brief_title>Study Bone Mineral Density Women With Breast Cancer Treated With Triptorelin Tamoxifen Exemestane Protocol IBCSG 25-02</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate change bone mineral density ( BMD ) among premenopausal woman randomize protocol IBC SG-25202 ( TEXT-2 ) receive either : A ) triptorelin ( GnRH analogue ) 5 year plus tamoxifen 5 year ; B ) triptorelin ( GnRH analogue ) 5 year plus steroidal aromatase inhibitor exemestane 5 year . - Evaluate serial serum marker bone remodel ( C-telopeptide , osteocalcin , bone-specific alkaline phosphatase ) investigate correlation BMD . - Evaluate relationship genetic variant CYP19A1 , ERα , ERß , IGF 1 BMD . - Evaluate serial serum growth factor ( IGF-1 IGFBP-3 ) investigate whether time course correlate BMD . - Explore role serum IGF-1 IGFBP-3 biomarkers disease outcome ( disease-free survival ) . ( exploratory ) OUTLINE : Blood sample collect baseline periodically 6 year . Serum marker bone remodel serum growth factor level measure . Bone mineral density L1-L4 ( postero-anterior ) region spine femoral neck hip measure DEXA baseline periodically 6 year . Any surplus serum store use unspecified future research .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patient must eligible enrolled TEXT2 trial prior enrol TEXTBone Serial bone marrow density ( BMD ) measurement must take within institution Hormone receptor positive PATIENT CHARACTERISTICS : See Disease Characteristics Premenopausal No bone fracture past 6 month , investigator 's judgement , could relate bone fragility No clinical biochemical malabsorption syndrome , know vitamin D deficiency , active hyper hypoparathyroidism , Paget 's disease No uncontrolled thyroid disease , Cushing disease , pituitary diseases No bone disease ( include osteomalacia osteogenesis imperfecta ) PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 6 month since prior concurrent bisphosphonate therapy ( bone therapy PTH strontium ) At least 6 month since prior glucocorticoid ( &gt; 5 mg prednisone equivalent ) &gt; 1 month At least 12 month since prior anticonvulsant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>